Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Alkermes

Gilead Sciences

Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.

3 Top Pharma Stocks to Buy Now: February 2024

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics

2Seventy Bio

Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the two companies said on Tuesday.

2seventy bio to sell experimental cell therapies to Regeneron

Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

Arista Networks

Bank of New York Mellon

Netflix

Progressive

We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.

5 U.S. Corporate Giants to Buy on Solid Economic Data

AstraZeneca

Vertex Pharmaceuticals

AstraZeneca appears to be an underrated growth stock. Regeneron Pharmaceuticals stands out as a perpetual market leader.

3 Magnificent Stocks to Buy and Hold Forever

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline

Sanofi

The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, the companies said on Thursday.

US FDA approves Dupixent to treat younger kids with esophageal condition

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo   Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs   EoE is one of five FDA-approved indications for Dupixent in the U.S. for which type 2 inflammation is an underlying driver Paris and Tarrytown, N.Y. January 25, 2024.

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Intuitive Surgical

Medtronic

Blue-chip healthcare stocks tend to be among the top portfolio picks for long-term investors today. Though their blue-chip status implies maturity, which they have, it also implies that the companies have limited growth prospects.

3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024

Gartner

Martin Marietta Materials

NVIDIA

We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.

S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks

The biotech space is booming right now, and investors can find considerable opportunities Regeneron has both a blockbuster portfolio and promising pipeline, and has delivered strong returns. Vertex makes billions a year from just four products, but a new approval may have just unlocked more growth.

2 Smart Growth Stocks to Buy Hand Over Fist in 2024

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

Amgen

Centene

Cencora Inc

Catalent

Merck

Moderna

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Arcellx

Beam Therapeutics

Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent achieved clear or almost clear skin and nearly four times as many had improvement in itch, compared with placebo TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know

There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since the ball dropped in Times Square.

3 health care stocks off to strong starts in 2024

Regeneron CEO Leonard Schleifer detailed the biotech company's newest ventures in the pharmaceutical industry.

Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.

Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)

Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 billion, despite generating substantially lower revenues compared to larger Pharmas such as, e.g., Gilead Sciences and Bristol Myers Squibb. Regeneron has consistently delivered profitable net income, however, and management may be prepared to start paying a dividend soon.

News for Regeneron Pharmaceuticals Stock (REGN)